Evidence map›Paper›PMID 29915283›Full record

ArticleCancer gene therapy2018

Upregulation of microRNA-3129 suppresses epithelial ovarian cancer through CD44.

Xiaochun Sun, Manhua Cui, Lingling Tong, Aichen Zhang, Kun Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Cancer gene therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Emerging Therapeutic Agents for Colorectal Cancer.Molecules (Basel, Switzerland) · 2021
    Review
  4. Article
  5. Article
  6. Article
  7. CD44 as a tumor biomarker and therapeutic target.Experimental hematology & oncology · 2020
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Xiaochun SunDepartment of Obstetrics and Gynecology, The Second Hospital of Jilin University, Changchun, 130041, China.
Manhua CuiDepartment of Obstetrics and Gynecology, The Second Hospital of Jilin University, Changchun, 130041, China. jaddycui@aol.com.
Lingling TongDepartment of Obstetrics and Gynecology, China-Japan Union Hospital of Jilin University, Changchun, 130021, China.
Aichen ZhangDepartment of Obstetrics and Gynecology, China-Japan Union Hospital of Jilin University, Changchun, 130021, China.
Kun WangDepartment of Obstetrics and Gynecology, China-Japan Union Hospital of Jilin University, Changchun, 130021, China.
Jilin University · CNSecond Affiliated Hospital of Jilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The purpose of this work is to evaluate whether human microRNA-3129 (hsa-miR-3129) may functionally regulate cancer development, possibly through downstream target CD44 in human epithelial ovarian cancer (EOC). Direct targeting of hsa-miR-3129 on human CD44 transcript was evaluated using a dual-luciferase reporter assay. Gene expression of hsa-miR-3129 in immortal EOC cell lines was evaluated by qRT-PCR. Lentivirus-mediated hsa-miR-3129 upregulation or downregulation was conducted in SK-OV-3 and CAOV-3 cells, in which endogenous hsa-miR-3129 and CD44 expressions were then measured. In hsa-miR-3129 upregulated or downregulated EOC cells, functional assays were applied to evaluate EOC proliferation, bufalin chemoresistance in vitro, or xenotransplantation in vivo. Moreover, CD44 was ectopically overexposed in hsa-miR-3129 upregulated EOC cells to functionally evaluate the correlation between hsa-miR-3129 and CD44 in EOC. Dual-luciferase reporter assay confirmed hsa-miR-3129 directly binds CD44. QRT-PCR revealed that hsa-miR-3129 was substantially downregulated in EOC cell lines. In SK-OV-3 and CAOV-3 cells, lentivirus-induced hsa-miR-3129 upregulation downregulated CD44 whereas hsa-miR-3129 downregulation did not affect CD44 expression. Hsa-miR-3129 upregulation had significant anti-cancer effects by inhibiting EOC proliferation, increasing bufalin chemoresistance, and suppressing xenotransplantation. On the other hand, overexpressing CD44 reversed the anti-cancer functions by hsa-miR-3129 upregulation in EOC cells. In conclusion, Has-miR-3129 is a functional regulator, possibly through reverse targeting on CD44, in EOC.

Indexed as

Carcinoma, Ovarian EpithelialFemaleHumansHyaluronan ReceptorsMicroRNAsOvarian NeoplasmsUp-RegulationCD44 protein, humanHyaluronan ReceptorsMicroRNAsMIRN3129 microRNA, human

Identifiers

PMID29915283
OpenAlexW2808423136

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.